Key result
COL6A3-derived endotrophin is linked to obesity-related coronary artery disease risk as a key mediator.
Observational
Answers are grounded in this paper and cite their sources.
This proteogenomic analysis identifies COL6A3-derived endotrophin as a key mediator linking obesity to coronary artery disease, highlighting it as a potential therapeutic target.
Obesity strongly increases the risk of cardiometabolic diseases, yet the underlying mediators of this relationship are not fully understood. Given that obesity strongly influences circulating protein levels, we investigated proteins mediating the effects of obesity on coronary artery disease, stroke and type 2 diabetes. By integrating two-step proteome-wide Mendelian randomization, colocalization, epigenomics and single-cell RNA sequencing, we identified five mediators and prioritized collagen type VI α3 (COL6A3). COL6A3 levels were strongly increased by body mass index and increased coronary artery disease risk. Notably, the carboxyl terminus product of COL6A3, endotrophin, drove this effect. COL6A3 was highly expressed in disease-relevant cell types and tissues. Finally, we found that body fat reduction could reduce plasma levels of COL6A3-derived endotrophin, indicating a tractable way to modify endotrophin levels. In summary, we provide actionable insights into how circulating proteins mediate the effects of obesity on cardiometabolic diseases and prioritize endotrophin as a potential therapeutic target.
No takes yet. Share an insight, caveat, or question.
Yoshiji et al. (2025) conducted an observational in Obesity and cardiometabolic diseases. Obesity (Body mass index) was evaluated on Coronary artery disease, stroke, and type 2 diabetes. Proteome-wide Mendelian randomization identified COL6A3-derived endotrophin as a key mediator of the effect of obesity on coronary artery disease risk.
Synapse has enriched 10 related papers. Consider them for comparative context: